Evidence has accumulated that asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. ADMA inhibits vascular NO production at concentrations found in pathophysiological conditions; it also causes local vasoconstriction when infused intra-arterially. ADMA is increased in the plasma of humans with hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, chronic heart failure, and other clinical conditions. Increased ADMA levels are associated with reduced NO synthesis as assessed by impaired endothelium-dependent vasodilation or reduced NO metabolite levels. In several prospective and cross-sectional studies, ADMA has evolved as a marker of cardiovascular risk. Moreover, prospective clinical studies have suggested that it may play a role as a novel cardiovascular risk factor. Zoccali and coworkers were the first to show that elevated ADMA is associated with a three-fold increased risk of future severe cardiovascular events and mortality in patients undergoing hemodialysis. Valkonen and coworkers demonstrated in a nested case-control study that elevated ADMA was associated with a four-fold increased risk for acute coronary events in clinically healthy, nonsmoking men. In patients with stable angina pectoris, preinterventional ADMA indicates the risk of developing restenosis or severe clinical events after coronary intervention. Furthermore, in humans with no underlying cardiovascular disease who are undergoing intensive care unit treatment, ADMA is a marker of the mortality risk. A number of additional prospective clinical trials are currently under way in diverse patient populations, among them individuals with congestive heart failure, cardiac transplantation patients, and patients with pulmonary hypertension.
Introduction
Evidence has accumulated in recent years that the endothelial production and release of nitric oxide (NO) plays a crucial role in the maintenance of physiological vascular tone and structure. Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of NO synthase. It inhibits vascular NO production at concentrations found in pathophysiological conditions, and also causes local vasoconstriction when infused intra-arterially. Thus, elevated ADMA levels may explain the 'L-arginine paradox', that is, the observation that supplementation with exogenous L-arginine improves NO-mediated vascular functions in vivo, although its baseline plasma concentration is about 25-fold higher than the K m of the isolated, purified endothelial NO synthase in vitro.
Dysfunction of the endothelial L-arginine/NO pathway is a common mechanism by which several cardiovascular risk factors mediate their deleterious effects on the vascular wall. Among them are hypercholesterolemia, 1 hypertension, 2 smoking, 3 diabetes mellitus, 4 hyperhomocysteinemia, 5 and vascular inflammation. 6 Vallance and coworkers first described ADMA as an endogenous inhibitor of NO synthase in 1992. 7 Since their initial observation, the circulating concentration of ADMA has been shown to be increased in humans with hypercholesterolemia, atherosclerosis, hypertension, chronic renal failure, congestive heart failure, diabetes mellitus, and other cardiovascular and metabolic diseases. Increased ADMA levels are associated with reduced NO synthesis and may therefore be a link between many other known and evolving cardiovascular risk factors and the progression of vascular disease. This review focuses on the evidence that has been gathered from clinical studies relating ADMA concentration to disease outcome.
Association of ADMA with cardiovascular disease: evidence from epidemiological studies
Numerous studies have been published that have demonstrated a relationship between high ADMA concentration and cardiovascular disease. Elevated ADMA has a high prevalence in hypercholesterolemia, 1 hyperhomocysteinemia, 8 diabetes mellitus, 9 peripheral arterial occlusive disease, 10 hypertension, 11, 12 chronic heart failure, 13 coronary artery disease, 14 and other diseases ( Table 1 ). All of the studies cited above were designed as case-control studies, thereby not allowing a conclusion about the possible cause-effect relationship between ADMA and cardiovascular diseases. However, the observation that ADMA levels increased early during the development of atherosclerosis suggested that ADMA had the potential to be not only a marker but also a mediator of vascular lesions. Data have recently accumulated from a series of cross-sectional clinical studies that confirm this hypothesis.
Miyazaki and coworkers 23 performed a study on 116 clinically healthy humans in whom intima-media thickness in the common carotid artery was determined. This had previously been shown to be a surrogate marker for atherosclerosis progression. In stepwise regression analysis including multiple cardiovascular risk markers they found that ADMA concentration was significantly associated with carotid intima-media thickness.
In another study a similar approach was used to assess intima-media thickness as determined by high-resolution ultrasound analysis in 90 patients with end-stage renal disease who were undergoing longterm hemodialysis. 24 Carotid intima-media thickness was related to various potential risk factors in a multiple regression analysis. Confirming the data of Miyazaki and coworkers, 23 it was found that ADMA was highly significantly correlated with intima-media thickness in this high-risk population. Furthermore, in an extension of previous data, the progression of intimal thickening during 1 year of follow-up was best predicted by initial ADMA and C-reactive protein levels.
Valkonen and coworkers 14 performed a nested casecontrol study including 150 middle aged, nonsmoking men from eastern Finland. They found that those whose ADMA concentration was within the highest quartile of the distribution in this population (i.e. Ͼ0.62 mol/l) had a 3.9-fold elevation of the risk for acute coronary events compared with the other quartiles.
In a multicenter case-control study including a total of 816 patients with objectively proven coronary artery disease and matched controls, we recently found that ADMA was the marker with the best discriminative power to differentiate between cases and controls. 25 A close relationship has also been established between insulin resistance and ADMA by the work of Stühlinger et al. 21 These investigators assessed insulin S20 RH Böger Vascular Medicine 2005; 10: S19-25 sensitivity in a group of 64 nondiabetic people using the insulin-glucose clamp technique. They found that a tight linear relationship existed between steady state plasma glucose (a measure of insulin resistance) and plasma ADMA. These data indicate that elevation of ADMA occurs before the manifestation of overt diabetes mellitus, which is also associated with elevated plasma ADMA. 9
ADMA is a novel cardiovascular risk factor: evidence from prospective clinical trials
In the first prospective trial studying ADMA as a potential new cardiovascular risk factor, at the University Hospital Hamburg-Eppendorf, we measured plasma ADMA as well as plasma levels of conventional and emerging cardiovascular risk factors in 225 patients on hemodialysis. After a median 33.4 months of follow-up, 120 major cardiovascular events and a total of 83 deaths (53 vascular deaths) had occurred. In a Cox's proportional hazards model ADMA and age were the strongest predictors of cardiovascular events and total mortality. 15 Although the median plasma ADMA concentration in this population (2.52 mol/l) was higher than in healthy normal adults (usually below 1 mol/l), patients with an ADMA concentration above the 75th percentile within this group had a three-fold higher risk of death from any cause than those with ADMA levels below the median.
In another prospective study, Lu and coworkers 26 addressed the question of whether ADMA may predict outcome after percutaneous coronary intervention in patients with stable angina pectoris. A total of 153 consecutive patients were followed for a median of 16 months. There were 51 major cardiovascular events during follow-up. There was a clear increase in risk with rising ADMA levels, which was independent of other potential confounding factors in a multifactorial Cox's regression analysis (including age, smoking, hypercholesterolemia, the use of stents, and others). The remarkable outcome of this study is that ADMA levels were within a range that many would consider as 'normal'; patients in the lowest tertile of ADMA had a median circulating concentration of 0.42 mol/l compared with 0.75 mol/l in the highest tertile.
Nijveldt and coworkers analysed potential predictors of death in patients undergoing treatment on a multidisciplinary intensive care unit. They included patients with multiple organ failure and found that ADMA was the strongest predictor of death, with a 17-fold excess in mortality for patients in the highest ADMA quartile compared with those in the lowest quartile. 27 ADMA was significantly associated with hepatic failure, and with lactic acid and bilirubin concentrations, suggesting that hepatic function is an important determinant of circulating ADMA concentration.
The currently available data on ADMA from prospective clinical studies are summarized in Table 2 . Additional prospective clinical studies have been initiated in patients with congestive heart failure, acute coronary syndrome, stable coronary heart disease, heart transplantation, and pulmonary hypertension. These data will enable us more precisely to define the role of ADMA as an emerging cardiovascular risk factor.
The pathophysiological link between ADMA and cardiovascular disease: evidence from experimental studies in humans
Experimental studies performed in vitro or in animal models have recently been summarized in several reviews. [28] [29] [30] This paper will therefore focus on data generated in humans.
In-vivo pathophysiological studies in humans have been performed by several groups of investigators. These data shed more light on the relationship between ADMA and vascular disease.
Intra-arterial infusion of ADMA into the brachial artery significantly reduced forearm blood flow. 31 However, ADMA concentrations reached in the local circulation after intra-arterial infusion by far outstrip those that can be measured in patients. Thus, two studies in which ADMA was administered intravenously added data to the dose-response relationship of ADMA in humans. In one study, ADMA was infused to reach a systemic plasma concentration of about 2.6 mol/l, 32 which caused a significant elevation of arterial blood pressure and systemic vascular resistance, reduced cardiac output and heart rate, and decreased the vascular response to exercise. In another ADMA and cardiovascular disease S21 Vascular Medicine 2005; 10: S19-25 study it was shown that ADMA decreased plasma cyclic guanosine monophosphate concentrations at pathophysiologically relevant concentrations, whereas renal plasma flow and glomerular filtration rate were reduced only at very high concentrations. 33 Chan and coworkers studied the adhesion of peripheral blood monocytes to cultured human endothelial cells. They found that the adhesiveness index was related to the circulating ADMA level of the patient from whom the monocytes were isolated. Moreover, when they manipulated the ratio of L-arginine over ADMA by giving supplemental L-arginine, they found that monocyte adhesion normalized during 12 weeks of treatment. 34 Taken together, the above mentioned studies provide a plethora of evidence that ADMA modulates endothelial NO synthase activity within the concentration range found in patients with vascular and metabolic diseases. Moreover, this evidence also suggests that even small modifications of ADMA significantly change vascular NO production, vascular tone, and systemic vascular resistance.
One important question in interpreting and understanding these findings and their relationship to ADMA plasma or serum levels measured in prospective clinical trials is the following: why do such small differences in circulating ADMA concentration as reported from prospective trials indicate such dramatic increases in cardiovascular event rate if such high levels of ADMA need to be reached during its systemic administration? The current interpretation shared by many experienced investigators in the field is that circulating levels of endogenous ADMA are the result of a 'spillover' from ADMA released within the cytosol during protein degradation. As diemthylarginine dimethylaminohydrolase (DDAH) enzymatic activity is present in many cells, and as ADMA is rapidly cleared from plasma, small changes in circulating levels may indicate large changes in local and/or intracellular ADMA concentration that clearly affect NO production and function. However, when ADMA is administered exogenously, it enters the circulation first and has to be transported into cells by CAT (the cationic amino acid transporter system y ϩ ) before it can affect cellular function. Much higher increases in plasma ADMA must therefore be attained to induce pathophysiological changes when exogenous ADMA is administered.
Measurement of ADMA in serum and plasma: methodological considerations and clinical relevance as a diagnostic tool
Research into ADMA was an exotic, purely experimental topic during the 1990s. However, as the above data show, it is now coming of age as an emerging cardiovascular risk factor. Currently, effort is being made to define the normal range of ADMA concentration in healthy humans of different age groups and of both sexes. Moreover, an international research initiative has undertaken a correlation of analytical methods, in order to allow the correlation of data measured in different laboratories around the world. Finally, besides elaborate analytical methods such as highperformance liquid chromatography and mass spectrometry, more widely accessible and less time consuming (and therefore cheaper) ways of measuring ADMA have become available with the development and validation of a novel competitive enzyme immunoassay that allows the sensitive and specific assessment of ADMA levels. 35, 36 As the scene is set for a wider application of ADMA measurement in clinical routine, the question is: who should be tested? ADMA is elevated in association with almost all traditional cardiovascular risk factors and in patients with established cardiovascular or metabolic disorders. However, its concentration shows significant variability even within these patient populations. Moreover, multivariate regression analyses that have taken into consideration all of the traditional and some other novel risk factors have shown that ADMA remains independently associated with cardiovascular risk or total mortality even after adjustment for the other risk factors has been performed.
The steadily increasing number of prospective clinical trials show that ADMA not only helps to discriminate between health and cardiovascular disease (for which there are other established diagnostic criteria), but these data point out that, even within a group of patients who have previously been regarded as homogeneous for their similar risk factor profile, ADMA is a tool that can be used to identify individuals with a comparatively high probability of experiencing a major event. There is therefore the potential that cardiovascular risk assessment, which currently is achieved by risk factor scores such as the Framingham risk score, 37 the PROCAM risk score, 38 or the risk charts developed by the European Society of Cardiology, 39 can be strengthened by adding ADMA as another risk indicator. This may hold especially true for patients who do not clearly fall into the high-risk (i.e. greater than 20% risk for a major event during the subsequent 10 years) or lowrisk (i.e. below 10% risk) categories, but who fall within the 'grey zone' of intermediate risk.
Thus, ADMA levels will be helpful in estimating the risk for patients who deserve intensified treatment for the prevention of cardiac events. L-arginine may be one means of specifically antagonizing the deleterious effects of ADMA on endothelial function via nutritional supplementation in primary and secondary prevention.
When ADMA is elevated: therapeutic consequences?
Clinical and experimental evidence suggests that elevation of ADMA causes a relative L-arginine deficiency, even in the presence of 'normal' L-arginine plasma concentrations. As ADMA is a competitive inhibitor of NO synthase, its inhibitory action can be overcome by increasing the concentration of this enzyme's natural substrate, L-arginine. 40, 41 Thus, it can be predicted that nutritional supplementation with L-arginine may help to restore the physiological balance by normalizing the L-arginine/ADMA ratio, whereas it will have little or no effect on humans with no disturbed L-arginine/ADMA balance. This view is supported by data from experimental studies with L-arginine supplementation.
Azuma and coworkers showed, in an experimental study, that ADMA accumulates in regenerated endothelial cells after balloon angioplasty. 42 It is well known that regenerated endothelial cells growing at the site of an arterial injury lack full functional capacity, with a major defect in the L-arginine-NO pathway. 43 This finding may explain why the local or systemic administration of L-arginine improves local arterial function after injury. 44 Few patients experience pathologically low L-arginine concentrations. However, clinical and experimental evidence suggests that elevation of ADMA may cause a relative L-arginine deficiency, even in the presence of 'normal' L-arginine levels. ADMA is a competitive inhibitor of nitric oxide synthase, so its inhibitory action can be overcome by increasing the concentration of the enzyme's substrate, L-arginine. The studies cited above have shown that ADMA levels may increase in situations associated with cardiovascular diseases, in which elevated ADMA concentration is one possible explanation for endothelial dysfunction and decreased NO production.
The beneficial vascular effects of cholesterollowering drugs -statins -have been shown to depend in part on their ability to upregulate endothelial NO synthase gene expression. 45 However, in clinical studies, statins failed to improve endothelium-dependent vasodilation in about as many studies as there were in favour of this hypothesis. Once more, this discrepancy may be resolved with the help of ADMA. Janatuinen et al 46 recently found that pravastatin was able to enhance myocardial blood flow (measured by positron electron resonance tomography) only in patients with a low ADMA level, whereas this drug was ineffective in those with an elevated ADMA. We speculated that ADMA may block NO synthase despite its upregulated gene expression after statin treatment, and that this blockade may be overcome by L-arginine supplementation. 47 Indeed, we found in a randomized, controlled trial that, in patients with an elevated ADMA concentration, simvastatin enhanced endothelium-dependent vasodilation only when it was combined with supplemental nutritional L-arginine. 48 Thus, ADMA may explain the results of clinical trials in which L-arginine was shown either to improve endothelial function or fail to do so, a discrepancy that has so far remained unexplained and which has previously been called the 'L-arginine paradox'. 40 Moreover, the ability of L-arginine to counteract the detrimental vascular effects of ADMA and thereby improve endothelial function as well as the symptoms of vascular disease demonstrates that the risk associated with elevated ADMA is modifiable. This is another critical aspect that needs to be addressed before one may call ADMA an 'emerging cardiovascular risk factor'.
The observation of an elevated ADMA concentration in a given patient may therefore justify L-arginine supplementation in order to improve the ability of the endothelium to generate NO, and thereby counteract the adhesion of circulating blood cells, reverse vasoconstriction, and attenuate the production of oxygen-derived free radicals.
